I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2025 Q3, the actual value is USD 136.56 M.
EPS: As of FY2025 Q3, the actual value is USD -0.14.
EBIT: As of FY2025 Q3, the actual value is USD -6.134 M.
Patient Services
- Revenue: $60,195 for the three months ended September 30, 2025, compared to $49,752 for the same period in 2024, representing a 21.0% increase. For the nine months ended September 30, 2025, revenue was $169,154 compared to $154,666 in 2024, a 9.4% increase.
- Direct Costs: $54,572 for the three months ended September 30, 2025, compared to $45,118 for the same period in 2024, a 21.0% increase. For the nine months ended September 30, 2025, direct costs were $152,802 compared to $141,137 in 2024, an 8.3% increase.
Dispensary
- Revenue: $75,895 for the three months ended September 30, 2025, compared to $48,210 for the same period in 2024, a 57.4% increase. For the nine months ended September 30, 2025, revenue was $187,761 compared to $132,329 in 2024, a 41.9% increase.
- Direct Costs: $63,072 for the three months ended September 30, 2025, compared to $40,091 for the same period in 2024, a 57.3% increase. For the nine months ended September 30, 2025, direct costs were $154,021 compared to $111,701 in 2024, a 37.9% increase.
Clinical Trials & Other
- Revenue: $474 for the three months ended September 30, 2025, compared to $1,939 for the same period in 2024, a 75.6% decrease. For the nine months ended September 30, 2025, revenue was $3,857 compared to $6,150 in 2024, a 37.3% decrease.
- Direct Costs: $0 for the three months ended September 30, 2025, compared to $326 for the same period in 2024. For the nine months ended September 30, 2025, direct costs were $279 compared to $946 in 2024, a 70.5% decrease.
Cash Flow
- Operating Cash Flow: Net cash used in operating activities was $27,820 for the nine months ended September 30, 2025, compared to $30,724 for the same period in 2024.
- Investing Cash Flow: Net cash used in investing activities was $2,014 for the nine months ended September 30, 2025, compared to net cash provided of $47,966 for the same period in 2024.
- Financing Cash Flow: Net cash provided by financing activities was $7,823 for the nine months ended September 30, 2025, compared to net cash used of $3,328 for the same period in 2024.
Future Outlook and Strategy
- Core Business Focus: The company has implemented initiatives to reduce costs and more effectively manage working capital, resulting in a 5% reduction in SG&A expenses compared to the prior year same quarter.
- Non-Core Business: The Clinical Trials segment is operated by a third party under a profit-sharing arrangement, which resulted in a write-off of the segment’s net assets for the nine months ended September 30, 2025.